Monocytes constitute a crucial immune cell type whose varied proportions and impaired functions are responsible for infection susceptibility and adverse outcomes.4,26 According to our data and previous studies, the number of monocytes with high expression of HLA-DR and CD14 (HLA-DPB1+ monocytes) is elevated in DLC patients,43 and MSC treatment can reduce the proportion of this monocyte subset. The gene discussed is HLA-DPB1; the disease is infection.